Basic Information
| LncRNA/CircRNA Name | NBR2 |
| Synonyms | NA |
| Region | GRCh38_17:43125610-43153671 |
| Ensemble | ENSG00000198496 |
| Refseq | NR_003108 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, RIP |
| Sample | steosarcoma tissues, cell lines(MG-63, U2OS, andSAOS-2, hFOB) |
| Expression Pattern | down-regulated |
| Function Description | In our study, we found that NBR2 expression was down-regulated in osteosarcoma tissues, and osteosarcoma cases with lower NBR2 expression exhibited a shorter overall survival time compared with those withhigher NBR2 expression. the NBR2 expression levelwas downregulated in osteosarcoma tissues from themetastasis group compared with that from the nonme-tastasis group. knocking down NBR2 couldenhance the EMT-related gene expression in MG-63 cells. |
| Pubmed ID | 30187965 |
| Year | 2018 |
| Title | LncRNA NBR2 inhibits epithelial-mesenchymal transition by regulating Notch1 signaling in osteosarcoma cells. |
External Links
| Links for NBR2 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |